文献速递头颈与中枢神经肿瘤

恩诺单抗维多汀治疗既往接受过治疗的晚期头颈癌的II期试验

Phase II Trial of Enfortumab Vedotin in Patients With Previously Treated Advanced Head and Neck Cancer.
PubMed 文献 · J Clin Oncol · 2024-10-31

EV-202研究为开放标签、多队列II期试验,评估恩诺单抗维多汀(EV)在既往接受过铂类及PD-1/PD-L1抑制剂治疗的复发/转移性头颈癌患者中的疗效与安全性,共46例可分析患者。确认客观缓解率为23.9%,疾病控制率56.5%,中位无进展生存期3.9个月,中位总生存期6.0个月。安全性与此前已知的EV安全性特征一致,未发现新的安全性信号。

要点

  • EV在重度经治的复发/转移性头颈癌中确认客观缓解率为23.9%,疾病控制率为56.5%。
  • 中位无进展生存期3.9个月,中位总生存期6.0个月,中位缓解持续时间在主要分析时未达到。
  • ≥3级治疗相关不良事件发生率为34.8%,常见治疗相关不良事件为脱发、疲乏和周围感觉神经病。

核心结论

  • EV在重度经治的头颈癌中显示出抗肿瘤活性,安全性与此前已知的EV安全性特征一致,未发现新的安全性信号。
  • 这些数据支持对不适合根治性局部治疗的晚期头颈癌进一步评估EV。

研究设计与样本

  • EV-202为开放标签、多队列、II期研究(ClinicalTrials.gov标识符:NCT04225117)。
  • 头颈癌队列纳入复发/转移性头颈癌患者,且既往因局部晚期/转移性疾病接受过铂类治疗和PD-1/PD-L1抑制剂。
  • EV按1.25 mg/kg静脉给药,每28天周期的第1、8、15天给药。
  • 主要分析纳入46例患者,均接受EV治疗,中位随访9.3个月。
  • 主要终点为研究者根据RECIST版本1.1评估的确认客观缓解率;次要终点包括研究者评估的缓解持续时间、疾病控制率和无进展生存期,以及总生存期和安全性。

主要发现

  • 多数患者(52.2%)在转移阶段既往接受过≥3线全身治疗。
  • 确认客观缓解率为23.9%,疾病控制率为56.5%,主要分析时中位缓解持续时间未达到( later data cutoff 时中位随访11.3个月,中位缓解持续时间为9.4个月)。
  • 中位无进展生存期3.9个月,中位总生存期6.0个月。
  • 发生率>20%的治疗相关不良事件为脱发(28.3%)、疲乏(26.1%)和周围感觉神经病(23.9%)。
  • 16例患者(34.8%)发生≥3级治疗相关不良事件;贫血和中性粒细胞计数降低各发生于2例患者(4.3%)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Despite advances in immunotherapy, unresectable recurrent/metastatic head and neck cancer (HNC) carries a poor prognosis, and effective treatments are needed. As nectin-4 is widely expressed in HNC, enfortumab vedotin (EV), a nectin-4-directed antibody-drug conjugate, was explored in HNC in EV-202 (ClinicalTrials.gov identifier: NCT04225117). METHODS: This open-label, multicohort, phase II study evaluated intravenous EV 1.25 mg/kg on days 1, 8, and 15 of each 28-day cycle. In the HNC cohort, eligible patients had recurrent/metastatic HNC and had received platinum-based therapy for locally advanced/metastatic disease and a PD-1/PD-L1 inhibitor. The primary end point was investigator-assessed confirmed objective response rate (ORR) per RECIST version 1.1. Secondary end points were investigator-assessed duration of response (DOR), disease control rate (DCR), and progression-free survival (PFS); overall survival (OS); and safety. RESULTS: The primary analysis included 46 patients; all received EV (median follow-up, 9.3 months). Most patients (52.2%) had ≥3 previous lines of systemic therapy in the metastatic setting. Confirmed ORR was 23.9%, DCR was 56.5%, and median DOR was not reached (median DOR was 9.4 months at a later data cutoff [median follow-up, 11.3 months]). Median PFS and OS were 3.9 and 6.0 months, respectively. Treatment-related adverse events (TRAEs) occurring in >20% of patients were alopecia (28.3%), fatigue (26.1%), and peripheral sensory neuropathy (23.9%). Sixteen patients (34.8%) experienced grade ≥3 TRAEs; anemia and decreased neutrophil count occurred in ≥1 patient (both n = 2; 4.3%). CONCLUSION: EV demonstrated antitumor activity in heavily pretreated HNC. Safety was consistent with the known safety profile of EV; no new safety signals were identified. These data support further evaluation of EV for advanced HNC not amenable to definitive local therapy.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Swiecicki PL, Yilmaz E, Rosenberg AJ, et al. Phase II Trial of Enfortumab Vedotin in Patients With Previously Treated Advanced Head and Neck Cancer. J Clin Oncol. 2024. PMID: 39481054. doi:10.1200/JCO.24.00646

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。